Becton Dickinson (BDX)  announced Sunday, April 23, that it will acquire medical technology peer C.R. Bard (BCR)  for $24 billion, the largest-ever deal for the 120-year-old buyer. Both BD and Bard are century-old medical device companies based in northern New Jersey.

Bard shareholders will receive $222.93 in cash and 0.5077 shares of BD stock per Bard share, or $317 per Bard share based on BD's closing price Friday of $185.29. The purchase price represents a 25.3% premium over Bard's Friday closing price of $253.07.

READ MORE: Becton Dickinson Acquires Medical Technology Peer C.R. Bard for Hefty Premium

This article was written by a staff member of TheStreet.

More from Video

Video: What to Expect From Microsoft's Earnings Thursday

Video: What to Expect From Microsoft's Earnings Thursday

Microsoft and IBM May Save the Stock Market

Microsoft and IBM May Save the Stock Market

Top Strategist Reveals the Stocks to Focus On For the Last Half of 2018

Top Strategist Reveals the Stocks to Focus On For the Last Half of 2018

Rewind: Jim Cramer Says the Cloud Kings Will Be the New FAANG

Rewind: Jim Cramer Says the Cloud Kings Will Be the New FAANG

Lee Munson: Not Peak FANG Yet

Lee Munson: Not Peak FANG Yet